<code id='8678C03127'></code><style id='8678C03127'></style>
    • <acronym id='8678C03127'></acronym>
      <center id='8678C03127'><center id='8678C03127'><tfoot id='8678C03127'></tfoot></center><abbr id='8678C03127'><dir id='8678C03127'><tfoot id='8678C03127'></tfoot><noframes id='8678C03127'>

    • <optgroup id='8678C03127'><strike id='8678C03127'><sup id='8678C03127'></sup></strike><code id='8678C03127'></code></optgroup>
        1. <b id='8678C03127'><label id='8678C03127'><select id='8678C03127'><dt id='8678C03127'><span id='8678C03127'></span></dt></select></label></b><u id='8678C03127'></u>
          <i id='8678C03127'><strike id='8678C03127'><tt id='8678C03127'><pre id='8678C03127'></pre></tt></strike></i>

          Home / fashion / Wikipedia

          Wikipedia


          Wikipedia

          author:Wikipedia    Page View:7232
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In